Expedited Review from IEC in case of change in study design [Regulatives / Guidelines]

posted by drgunasakaran1  – 2012-01-13 18:51 (5282 d 19:57 ago) – Posting: # 7937
Views: 3,518

Dear Mr.Prashant,

Change in the study design and increase in the sample size will not be eligible for Ethics Committee's Expedited approval.

Kindly be informed that as per the CDSCO's Minutes of the Meeting on matters relating to Global Clinical Trials Held On 17th October 2006 At IDMA Office - Mumbai, the following amendments require prior permission from DCGI along with Ethics committee full approval before implementation of the amendments.

i) Change of Principal Investigator
ii) Additional Patients to be recruited
iii) Major changes in protocol with respect to study design, dose and treatment options

For more details on the expedited review eligibility criteria for a study, check the following link
Expedited Approval Criteria

Dr Gunasakaran Sambandan MD
Disclaimer: The replies/posts are my personal opinions, and they do not represent my company's views on the same. LinkedIn

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
246 visitors (0 registered, 246 guests [including 23 identified bots]).
Forum time: 15:49 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5